Posso Hector, León-Maldonado Leith, Allen-Leigh Betania, Salmerón Jorge, Quiterio Manuel, Giuliano Anna R, Sudenga Staci L, Nyitray Alan G, Torres B Nelson, Abrahamsen Martha, Lazcano-Ponce Eduardo
Universidad de la Sabana. Chia-Cundinamarca, Colombia.
Cátedra Conacyt, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.
Salud Publica Mex. 2018 Nov-Dec;60(6):645-652. doi: 10.21149/8454.
Describe the natural history of anal HPV among men.
Prospective study among men 18-70 years (n=665), from Cuernavaca, Mexico who completed questionnaires and provided specimens (HPV genotyped) at enrollment and 1+ follow-up visit. HPV prevalence and incidence were estimated. Prevalence ratios were calculated with Poisson regression using robust variance estimation. Person-time for incident HPV infection was estimated using number of events modeled as Poisson variable for total person-months.
Anal infection prevalence: any HPV type=15%, high-risk=8.4%, HPV16=1.4%, tetravalent vaccine types (4vHPV)=4.4%, nonavalent vaccine types (9vHPV)=6.3%. Factors associated with prevalence: 50+ lifetime female sex partners (adjusted prevalence ratio, a PR=3.25, 95% CI:1.12- 9.47), 10+ lifetime male sex partners (aPR=3.06, 95%CI:1.4- 6.68), and 1+ recent male anal sex partners (aPR=2.28, 95%CI:1.15-4.5). Anal incidence rate: high-risk HPV=7.8/1000 person-months (95%CI:6.0-10.1), HPV16=1.8/1000 personmonths (95%CI:1.1-2.9),4vHPV=3.4/1000 person-months (95%CI:2.3-4.9) and 9vHPV=5.5/1000 person-months (95%CI:4.1-7.5).
Implementation of universal HPV vaccination programs, including men, is a public health priority.
描述男性肛门人乳头瘤病毒(HPV)的自然史。
对来自墨西哥库埃纳瓦卡的18至70岁男性(n = 665)进行前瞻性研究,这些男性在入组时及1次或更多次随访时完成问卷调查并提供标本(进行HPV基因分型)。估计HPV患病率和发病率。使用稳健方差估计的泊松回归计算患病率比值。将事件数建模为总人月数的泊松变量来估计新发HPV感染的人时。
肛门感染患病率:任何HPV类型为15%,高危型为8.4%,HPV16为1.4%,四价疫苗型(4vHPV)为4.4%,九价疫苗型(9vHPV)为6.3%。与患病率相关的因素:终生有50个以上女性性伴侣(调整患病率比值,aPR = 3.25,95%可信区间:1.12 - 9.47),终生有10个以上男性性伴侣(aPR = 3.06,95%可信区间:1.4 - 6.68),以及近期有1个或更多男性肛门性伴侣(aPR = 2.28,95%可信区间:1.15 - 4.5)。肛门发病率:高危型HPV为7.8/1000人月(95%可信区间:6.0 - 10.1),HPV16为1.8/1000人月(95%可信区间:1.1 - 2.9),4vHPV为3.4/1000人月(95%可信区间:2.3 - 4.9),9vHPV为5.5/1000人月(95%可信区间:4.1 - 7.5)。
实施包括男性在内的普遍HPV疫苗接种计划是公共卫生的优先事项。